UTHR

$595.940.89%-5.38

United Therapeutics Corp (UTHR)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$601.32

Offen:

$583.63

24-Stunden-Volumen:

349,014

Relatives Volumen:

0.65

Marktkapitalisierung:

$25.56B

Einnahmen:

$3.17B

Nettoeinkommen (Verlust:

$1.29B

KGV:

21.99

EPS:

$27.09

Netto-Cashflow:

$1.01B

1W Leistung:

+1.61%

1M Leistung:

+10.01%

6M Leistung:

+2.53%

1Y Leistung:

+36.27%

1-Tages-Spanne:

$578.28$602.40

1-Wochen-Bereich:

$589.62$609.99

52-Wochen-Spanne:

$430.02$609.99

United Therapeutics Corp Aktie (UTHR) Unternehmensprofil

Firmenname

United Therapeutics Corp

Sektor

Healthcare

Branche

Drug Manufacturers - Specialty & Generic

Telefon

(301) 608-9292

Adresse

1000 SPRING ST, SILVER SPRING, MD, USA

Mitarbeiter

1,400

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

SEC

UTHR-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

United Therapeutics Corp Aktie (UTHR) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-10-01	Hochstufung	BTIG Research	Neutral → Buy
2026-09-24	Eingeleitet	Goldman	Sell
2026-05-07	Hochstufung	Wells Fargo	Equal Weight → Overweight
2026-04-10	Eingeleitet	Raymond James	Outperform
2025-10-20	Eingeleitet	Wells Fargo	Underweight
2025-09-26	Eingeleitet	RBC Capital Mkts	Outperform
2025-06-02	Eingeleitet	Cantor Fitzgerald	Overweight
2025-04-25	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-04-21	Hochstufung	BofA Securities	Underperform → Neutral
2024-07-11	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-02-12	Hochstufung	Goldman	Sell → Neutral
2024-02-05	Eingeleitet	Leerink Partners	Outperform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2022-12-06	Eingeleitet	UBS	Buy
2022-12-05	Eingeleitet	Goldman	Sell
2022-10-11	Eingeleitet	Morgan Stanley	Overweight
2022-09-20	Bestätigt	BofA Securities	Underperform
2022-09-19	Resumed	Wedbush	Outperform
2022-02-11	Eingeleitet	BTIG Research	Neutral
2021-07-14	Hochstufung	Argus	Hold → Buy
2021-04-26	Resumed	Credit Suisse	Outperform
2021-02-01	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-09-14	Resumed	JP Morgan	Overweight
2020-06-25	Bestätigt	H.C. Wainwright	Neutral
2020-03-10	Hochstufung	Jefferies	Hold → Buy
2020-02-27	Hochstufung	Cowen	Market Perform → Outperform
2020-01-31	Hochstufung	JP Morgan	Neutral → Overweight
2019-12-03	Eingeleitet	BofA/Merrill	Underperform
2019-08-01	Hochstufung	Jefferies	Underperform → Hold
2019-08-01	Hochstufung	Ladenburg Thalmann	Neutral → Buy
2019-07-01	Hochstufung	Credit Suisse	Neutral → Outperform
2019-05-17	Hochstufung	UBS	Sell → Neutral
2019-05-09	Hochstufung	Credit Suisse	Underperform → Neutral
2018-10-12	Hochstufung	Standpoint Research	Hold → Buy
2018-08-08	Herabstufung	Credit Suisse	Neutral → Underperform
2018-04-03	Hochstufung	Credit Suisse	Underperform → Neutral
2018-02-22	Bestätigt	Barclays	Underweight
2018-01-18	Resumed	Credit Suisse	Underperform
2017-12-27	Bestätigt	Wedbush	Outperform
2017-04-27	Bestätigt	Wedbush	Outperform
2017-03-30	Eingeleitet	UBS	Sell
2017-03-16	Eingeleitet	Credit Suisse	Underperform

Finanzdaten der United Therapeutics Corp-Aktie (UTHR)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	3,182.70	2,877.40	2,327.50	1,936.30	1,685.50
Cost of revenue USD (M)	384.40	309.70	257.50	151.60	122.50
Gross profit USD (M)	2,798.30	2,567.70	2,070.00	1,784.70	1,563.00
Research and development USD (M)	550.00	481.00	408.00	322.90	540.10
Operating expenses USD (M)	1,690.20	1,500.40	885.10	805.00	1,007.10
Operating income USD (M)	1,492.50	1,377.00	1,184.90	979.70	555.90
Income before tax USD (M)	1,713.90	1,539.00	1,274.30	950.60	593.90
Income tax expense USD (M)	379.20	343.90	289.50	223.30	118.10
Net income USD (M)	1,334.70	1,195.10	984.80	727.30	475.80
Basic EPS USD/shares	30.13	26.44	21.04	15.98	10.60
Diluted EPS USD/shares	27.86	24.64	19.81	15.00	10.06
Basic weighted shares shares (M)	44.30	45.20	46.80	45.50	44.90
Diluted weighted shares shares (M)	47.90	48.50	49.70	48.50	47.30
Selling, general and administrative USD (M)	755.80	709.70	477.10	-	-

United Therapeutics Corp-Aktie (UTHR) Insiderhandel

ROTHBLATT MARTINE ANov 02 '26
Chairperson & CEO
Transaktion
Sale
Kosten
$596.22
#Aktien
9,500
Wert ($)
5,664,136
#Aktien Gesamt
324,443
ROTHBLATT MARTINE ANov 02 '26
Chairperson & CEO
Transaktion
Option Exercise
Kosten
$117.76
#Aktien
9,500
Wert ($)
1,118,720
#Aktien Gesamt
333,943
MARTINE ROTHBLATTNov 02 '26
Director
Transaktion
Proposed Sale
Kosten
$598.72
#Aktien
119,410
Wert ($)
71,493,155
#Aktien Gesamt
0
ROTHBLATT MARTINE AOct 30 '26
Chairperson & CEO
Transaktion
Option Exercise
Kosten
$117.76
#Aktien
9,500
Wert ($)
1,118,720
#Aktien Gesamt
333,943
ROTHBLATT MARTINE AOct 30 '26
Chairperson & CEO
Transaktion
Sale
Kosten
$600.09
#Aktien
9,500
Wert ($)
5,700,856
#Aktien Gesamt
324,443
ROTHBLATT MARTINE AOct 29 '26
Chairperson & CEO
Transaktion
Sale
Kosten
$594.78
#Aktien
9,500
Wert ($)
5,650,415
#Aktien Gesamt
324,443
ROTHBLATT MARTINE AOct 29 '26
Chairperson & CEO
Transaktion
Option Exercise
Kosten
$117.76
#Aktien
9,500
Wert ($)
1,118,720
#Aktien Gesamt
333,943
ROTHBLATT MARTINE AOct 28 '26
Chairperson & CEO
Transaktion
Option Exercise
Kosten
$117.76
#Aktien
9,500
Wert ($)
1,118,720
#Aktien Gesamt
333,943
ROTHBLATT MARTINE AOct 28 '26
Chairperson & CEO
Transaktion
Sale
Kosten
$585.49
#Aktien
9,500
Wert ($)
5,562,190
#Aktien Gesamt
324,443
ROTHBLATT MARTINE AOct 27 '26
Chairperson & CEO
Transaktion
Sale
Kosten
$587.73
#Aktien
9,500
Wert ($)
5,583,418
#Aktien Gesamt
324,443

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 02 '26	Sale	$596.22	9,500	5,664,136	324,443
ROTHBLATT MARTINE A	Chairperson & CEO	Nov 02 '26	Option Exercise	$117.76	9,500	1,118,720	333,943
MARTINE ROTHBLATT	Director	Nov 02 '26	Proposed Sale	$598.72	119,410	71,493,155	0
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 30 '26	Option Exercise	$117.76	9,500	1,118,720	333,943
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 30 '26	Sale	$600.09	9,500	5,700,856	324,443
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 29 '26	Sale	$594.78	9,500	5,650,415	324,443
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 29 '26	Option Exercise	$117.76	9,500	1,118,720	333,943
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 28 '26	Option Exercise	$117.76	9,500	1,118,720	333,943
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 28 '26	Sale	$585.49	9,500	5,562,190	324,443
ROTHBLATT MARTINE A	Chairperson & CEO	Oct 27 '26	Sale	$587.73	9,500	5,583,418	324,443

United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten

Oct 30, 2026

SGIOY vs. UTHR: Which Stock Is the Better Value Option? - Zacks Investment Research

Oct 30, 2026

OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates - Zacks Investment Research

Oct 30, 2026

Oct 28, 2026

Options exercised at $117.76 a share accompanied sales by United Therapeutics (UTHR) CEO's trusts. - Stock Titan

Oct 28, 2026

$100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga

Oct 28, 2026

United Therapeutics Rising Ahead of Next Earnings Report - FXEmpire

Oct 28, 2026

FDA clears United Therapeutics to begin Treprostinil-Iloprost trial - StreetInsider

Oct 28, 2026

Oct 27, 2026

CEO trusts exercised $117.76 options and sold 9,500 shares in United Therapeutics (UTHR). - Stock Titan

Oct 27, 2026

S&P 500 Futures Up in Premarket Trading; MSG Sports, United Therapeutics Lag - Barron's

Oct 27, 2026

Oct 26, 2026

United Therapeutics CEO sells $5.5M in stock By Investing.com - Investing.com Nigeria

Oct 26, 2026

Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 23 October - Investing.com Nigeria

Oct 26, 2026

United Therapeutics CEO sells $5.5M in stock - Investing.com

Oct 26, 2026

After exercising options at $117.76, United Therapeutics (UTHR) CEO trusts sell 9,500 shares. - Stock Titan

Oct 26, 2026

Oct 25, 2026

United Therapeutics (NDQ:UNTR): The Only Company Attempting Xenotransplantation At Scale! - Stocks Down Under

Oct 25, 2026

Oct 24, 2026

U.S. transgender billionaire Martine Rothblatt sells $5.5 million in United Therapeutics stock - Billionaires.Africa

Oct 24, 2026

Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock - Investing.com

Oct 24, 2026

Oct 23, 2026

United Therapeutics Gets FDA Clearance to Start Phase 2 SUMMIT Trial of Treprostinil Soft Mist Inhaler in PH-COPD - BioBuzz

Oct 23, 2026

United Therapeutics to build a $9 million hangar at Rochester's airport - Post Bulletin

Oct 23, 2026

Oct 22, 2026

United Therapeutics CEO Rothblatt sells $5.3m in UTHR stock - Investing.com

Oct 22, 2026

Is United Therapeutics Corp (UTHR) Overvalued After 3.8% Rally? - GuruFocus

Oct 22, 2026

Generation Park lands new facility to scale xeno-organ production - InnovationMap

Oct 22, 2026

United Therapeutics authorizes $2 billion buyback program - Investing.com

Oct 22, 2026

United Therapeutics Authorizes Up to $2 Billion Share Repurchase - TradingView

Oct 22, 2026

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization - Yahoo Finance

Oct 22, 2026

Oct 21, 2026

United Therapeutics CEO Martine Rothblatt sells $5.26m in stock - Investing.com

Oct 21, 2026

CEO trusts sell 9,500 United Therapeutics (UTHR) shares after exercising stock options. - Stock Titan

Oct 21, 2026

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 - Yahoo Finance

Oct 21, 2026

Oct 20, 2026

Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 19 October - Investing.com Nigeria

Oct 20, 2026

United Therapeutics CEO Rothblatt sells $5.16m in shares - Investing.com

Oct 20, 2026

United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500? - Yahoo Finance

Oct 20, 2026

United Therapeutics opens third xenograft production facility - Investing.com

Oct 20, 2026

A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. - Stock Titan

Oct 20, 2026

United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth - The Business Journals

Oct 20, 2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility - Yahoo Finance

Oct 20, 2026

United Therapeutics chairperson & CEO sells $5.08m in shares By Investing.com - Investing.com Nigeria

Oct 20, 2026

Oct 19, 2026

Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 October - Investing.com Nigeria

Oct 19, 2026

After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan

Oct 19, 2026

Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga

Oct 19, 2026

Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga

Oct 19, 2026

United Therapeutics (UTHR) Gains FDA Approval for SUMMIT Trial o - GuruFocus

Oct 19, 2026

Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan

Oct 19, 2026

United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price - ChartMill

Oct 19, 2026

Oct 17, 2026

United Therapeutics chairperson & CEO sells $5.19m in stock - Investing.com

Oct 17, 2026

Oct 16, 2026

Paul Mahon, United Therapeutics EVP, sells $4.5m in stock - Investing.com

Oct 16, 2026

After exercising options at $117.76 each, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan

Oct 16, 2026

An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan

Oct 16, 2026

Oct 15, 2026

United Therapeutics CEO Rothblatt sells $5.1m in shares By Investing.com - Investing.com Nigeria

Oct 15, 2026

After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares. - Stock Titan

Oct 15, 2026

Oct 14, 2026

A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan

Oct 14, 2026

United Therapeutics secures $381M settlement in patent dispute with competitor - The Business Journals

Oct 14, 2026

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research

Oct 14, 2026

Ähnlich wie UTHR